Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for CCNE1-Amplified Cancer Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCNE1 drug discovery. Select your target modality below to access sequence-verified, high-purity solutions."
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human CCNE1 Protein (Full Length / Truncated) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spec. |
View CCNE1 Products |
| Gene Delivery | CCNE1 Promise-ORF / Lentiviral Particles High-titer transduction-ready particles for stable cell line generation. |
View CCNE1 Products |
| Benchmark Ab | Anti-CCNE1 Recombinant Antibody Sequence-derived from clinical benchmark clones for Western Blot, IHC, and IP. |
View CCNE1 Products |
| Validator | CCNE1 siRNA Set Target-specific gene knockdown validation to confirm assay specificity. |
View CCNE1 Products |
| Related Target A | CDK2 (Cyclin-Dependent Kinase 2) Primary catalytic partner of CCNE1; critical for CDK2/CCNE1 complex kinase assays. |
View CDK2 Products |
| Related Target B | PKMYT1 (Membrane-Associated Tyrosine-and-Threonine-Specific C-Mitotic Kinase) Synthetic lethal partner in CCNE1-amplified cancers. |
View PKMYT1 Products |
| Related Target C | WEE1 G2 Checkpoint Kinase Synergistic pathway target for cell cycle checkpoint inhibition. |
View WEE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstitution of active CCNE1/CDK2 complex | Co-expressed or high-purity recombinant CCNE1 and CDK2 proteins with verified theoretical MW and high purity (>95%). |
| High-throughput screening of synthetic lethal inhibitors | High-titer CCNE1 Lentiviral Particles for rapid generation of stable CCNE1-overexpressing cell lines. |
| Lack of reliable positive controls | Clinical-grade benchmark recombinant antibodies for assay validation and target engagement studies. |
| Off-target assay noise | Sequence-verified siRNA sets for robust target knockdown and specificity control. |
Live CCNE1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Cyclin E1 (CCNE1) has emerged as a cornerstone strategy in addressing CCNE1-amplified gynecological and solid tumors, particularly high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC). Because direct transcription factor/cyclin inhibition presents structural challenges, the therapeutic landscape has evolved from direct inhibitors to targeting downstream and synthetic lethal nodes.
The race for CCNE1 therapeutics is intensifying, with major players shifting focus from traditional CDK inhibitors to selective CDK2 inhibitors and synthetic lethality partners like PKMYT1 and WEE1. As first-generation CDK2 and PKMYT1 inhibitors reach phase I/II clinical trials, the next wave of R&D is targeting CCNE1 degradation via PROTACs and molecular glues to overcome acquired resistance mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CDK2 Inhibitors | Pfizer, Incyte, Blueprint Medicines | HGSOC, TNBC, Endometrial Cancer | CCNE1/CDK2 kinase complex binding and activity assays (Requires high-purity recombinant proteins). |
| PKMYT1 Inhibitors | Repare Therapeutics, Roche | CCNE1-amplified Solid Tumors | Synthetic lethality screens (Requires CCNE1-overexpressing stable cell lines via Lentivirus). |
| PROTACs / Degraders | Cullgen, Dialectic Therapeutics | Resistant Solid Tumors | Ubiquitination and degradation validation (Requires sequence-verified benchmark antibodies). |